September 26th 2024
Dr Shallis discusses the ELEMENT-MDS trial in MDS and the potential of intervening with luspatercept before patients become RBC transfusion dependent.
August 8th 2024
Rory Shallis, MD, discusses the utility of luspatercept in the context of the phase 3 ELEMENT-MDS trial for patients with myelodysplastic syndrome.
October 18th 2022
Rory Shallis, MD, discusses the investigation of uproleselan in acute myeloid leukemia.